Pfizer has been working with BioNTech on a vaccine for COVID-19, and their early analysis suggests their vaccine candidate is over 90% effective. That would be a much higher than expected rate of efficacy from one of the earliest vaccine candidates for the virus. The U.S. Food and Drug Administration is looking for at least 50% efficacy from a COVID-19 vaccine.Q3 2020 hedge fund letters, conferences and morePfizer vaccine may be very effectiveThe interim analysis focused on the first 94 confirmed cases of COVID-19 among the over 43,000 volunteers who received either two doses of the vaccine or…
